AVTR vs AZTA: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

AVTR is the larger of the two ($10.18B market cap): the incumbent the market prices for continued execution (16.95x forward earnings, beta 0.95). AZTA is the smaller challenger ($1.87B), actually pricier on forward earnings (50.37x): more room to run, but more to prove. If you believe AZTA earns its premium (50.37x forward earnings, so the market expects more from it), AZTA fits. If you believe in paying less for profit, AVTR fits at 16.95x.

AVTR vs AZTA: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricAVTRAZTAWhat it tells you
Market cap$10.18B$1.87BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E16.9550.37Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.951.47Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range76% of range85% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.751.34How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: AVTR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how AVTR and AZTA affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AVTR and AZTA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AVTR and AZTA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Avantor (AVTR) do?

Avantor, Inc. is a global provider of high-purity materials, consumables, equipment, and specialized services used across biopharma, healthcare, education, government, and advanced technology markets. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company sells everything from high-purity chemicals and reagents, lab supplies, and customized excipients to single-use assemblies, chromatography resins, and fluid handling systems. It reorganized around two reporting segments (Laboratory Solutions and a Bioscience and Medtech Products grouping), and a large share of its revenue is recurring consumables that customers reorder repeatedly, which gives the model a razor-and-blade quality tied to laboratory activity and biologic manufacturing volumes.

Full AVTR guide

What does Azenta (AZTA) do?

Azenta, Inc., based in Burlington, Massachusetts, is what remains of Brooks Automation after it sold its semiconductor robotics business in 2022. It now has two segments. Sample Management Solutions (about $344 million of fiscal 2026 revenue) sells automated freezers and storage systems, cryogenic equipment, sample tubes and consumables, and runs repositories that store millions of biological samples for drug companies, biobanks and research groups. Multiomics (about $277 million) is GENEWIZ, which sells Sanger sequencing, next-generation sequencing and gene synthesis as a service. In July 2026 Azenta sold B Medical Systems, its vaccine cold-chain business, so it is now reported as discontinued.

Full AZTA guide

AVTR vs AZTA: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • AVTR drivers: Revival transformation program; Recurring consumables and bioprocessing exposure.
  • AZTA drivers: Margin recovery from cost cuts; Gene synthesis replacing Sanger sequencing.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Avantor's return to organic growth is only one quarter old, and full-year 2026 organic growth guidance of 0.75% to 1.25% shows how weak the first half was, so the recovery could stall if biopharma and academic customers keep spending cautiously. For AZTA, execution is the main risk.

AVTR or AZTA: which should you pick?

If the story you believe is AVTR's (Revival transformation program), AVTR is the more direct way to own it; if it is AZTA's (Margin recovery from cost cuts), AZTA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AVTR and AZTA guides.

AVTR vs AZTA: the full fundamentals

AVTR. As of November 2026 Avantor trades at about 17x forward earnings and about 1.5x sales, down from mid-October as the stock gave back part of its summer rally despite a third straight beat and raised guidance. It still sits at a discount to larger, higher-margin tools peers because of its slower growth and higher leverage. The 13 analysts tracked by Yahoo Finance hold an average target of about $17.35, and RBC and Deutsche Bank both lifted their targets to $17 after the Q3 report while keeping neutral ratings.

AZTA. At ~$44.51 and roughly 43 to 44 million shares, Azenta's market value is about $1.9 billion, or about $1.4 billion after subtracting cash and securities. That is roughly 2.9 times fiscal 2026 revenue and about 2.2 times the midpoint of fiscal 2027 guidance after cash, and about 50 times the ~$0.89 of EPS analysts expect for fiscal 2027. GAAP results were a loss of $3.50 per share from continuing operations because of the impairment. Before the November report, MarketBeat showed a consensus Hold rating with an average target near $40 to $41; Yahoo Finance's five-analyst consensus now reads Buy with a mean target near $52.60, after Needham moved to $57.

Headline figures (approximate, November 2026): AVTR shows revenue (ttm) ~$6.64B, q3 2026 revenue ~$1.70B (+4.6% YoY, organic +5.2%), q3 2026 adjusted eps $0.22 vs $0.21 consensus, gross / operating margin ~32% / ~8%; AZTA shows revenue (fy2026, continuing ops) ~$622 million (Q4 up ~5%), fy2027 revenue guidance ~$648M to $660M, adjusted eps (fy2026 / q4) ~$0.48 / ~$0.28 vs ~$0.11 est., adjusted ebitda margin (fy2026) ~9.4%.

The bottom line: AVTR vs AZTA

AVTR and AZTA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AVTR and AZTA exposure against your real portfolio. It is not an investment adviser.

Wondering how AVTR or AZTA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Avantor

Ask Walnut's AI anything about AVTR and see how it fits what you own.

FAQ

What is the difference between AVTR and AZTA?

+

Avantor, Inc. Azenta, Inc., based in Burlington, Massachusetts, is what remains of Brooks Automation after it sold its semiconductor robotics business in 2022. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AVTR or AZTA the better stock?

+

Neither is universally better. AVTR is the larger incumbent; AZTA is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AVTR or AZTA?

+

On forward P/E (as of November 2026), AVTR trades at 16.95x and AZTA at 50.37x, so AVTR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AVTR and AZTA?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AVTR vs AZTA?

+

AVTR: Avantor's return to organic growth is only one quarter old, and full-year 2026 organic growth guidance of 0.75% to 1.25% shows how weak the first half was, so the recovery could stall if biopharma and academic customers keep spending cautiously. Margins are under pressure from inflation and product mix, and VWR adjusted operating margin fell year over year in Q3. The company carries meaningful leverage (about $3.7 billion of debt and about $0.46 billion of cash, adjusted net leverage near 3.1x), which amplifies the downside if EBITDA disappoints and constrains flexibility. The turnaround depends heavily on execution by a leadership team that only filled its CFO seat permanently in September 2026. Europe was a soft spot in Q3, and the shares fell about 13% in the month to November 20 even after raised guidance, so sentiment remains fragile. It also competes against much larger, better-capitalized peers such as Thermo Fisher, and its exposure to biopharma capex, academic funding cycles, and currency swings adds cyclicality. Any renewed destocking or funding cuts in life sciences would pressure results. AZTA: Execution is the main risk. Azenta reaffirmed growth and margin targets in February 2026, then cut them in May alongside a $149 million impairment, and the stock fell about 25%. Guidance for fiscal 2027 asks for 3% to 5% organic growth and wider margins at the same time, under an interim CEO. Several law firms, including Rosen and Pomerantz, have announced investigations into possible securities claims tied to the May guidance cut and the August CEO resignation; as of early November 2026 no filed complaint was confirmed, but one could follow. Sanger sequencing keeps shrinking, and gene synthesis is crowded, with Twist Bioscience, IDT (part of Danaher) and GenScript all larger in the market. The Elegen license and SynPlexity purchase are early bets that cut margin first. Automated Stores sales depend on customers' capital budgets and on fixing the quality problems. China drove gene synthesis growth (China revenue rose 23% in fiscal 2026), which exposes the company to US-China trade and biotech policy. Lower NIH and academic funding and slower biotech spending would also weigh on demand. After a ~20% one-day rise and a gain of about 34% over three months, the shares carry high expectations into fiscal 2027, at about 50 times forward EPS estimates of $0.89.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AVTR or AZTA; figures are approximate and dated (as of November 2026). Verify current data before investing.